5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2…
By L. Gianni, T. Pieńkowski, Y. Im, L. Tseng, Mei-Ching Liu, A. Lluch, E. Starosławska, J. R. De La Haba-Rodríguez, S. Im, J. Pedrini and 10 more. The Lancet Oncology, 2016
787 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/ed2985c171e64d4020233679cf076ebacd7bbed4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
Citations in the corpus
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018, background): “Neoadjuvant therapy— HER2 targeted therapy Long-term follow-up of NeoSphere trial suggests disease-free survival advantage parallels increased rate of pCR with pertuzumab- and trastuzumab-based therapy [52].”